Innate Pharma S.A. IPHYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.94M | 4.07M | 3.13M | 4.79M | 6.51M |
| Total Other Revenue | 6.51M | 6.83M | 7.02M | 7.10M | 7.22M |
| Total Revenue | 11.44M | 10.91M | 10.15M | 11.88M | 13.73M |
| Cost of Revenue | 46.64M | 48.47M | 49.39M | 48.15M | 47.24M |
| Gross Profit | -35.19M | -37.56M | -39.24M | -36.27M | -33.51M |
| SG&A Expenses | 20.33M | 21.33M | 21.91M | 21.71M | 21.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.96M | 69.80M | 71.30M | 69.86M | 68.89M |
| Operating Income | -55.52M | -58.89M | -61.15M | -57.98M | -55.16M |
| Income Before Tax | -55.36M | -56.06M | -55.81M | -52.78M | -50.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.36 | -56.06 | -55.81 | -52.78 | -50.09 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.36M | -56.06M | -55.81M | -52.78M | -50.09M |
| EBIT | -55.52M | -58.89M | -61.15M | -57.98M | -55.16M |
| EBITDA | -54.79M | -58.12M | -60.36M | -57.09M | -54.16M |
| EPS Basic | -0.60 | -0.61 | -0.62 | -0.61 | -0.60 |
| Normalized Basic EPS | -0.37 | -0.38 | -0.39 | -0.38 | -0.37 |
| EPS Diluted | -0.60 | -0.62 | -0.63 | -0.61 | -0.60 |
| Normalized Diluted EPS | -0.37 | -0.38 | -0.39 | -0.38 | -0.37 |
| Average Basic Shares Outstanding | 372.14M | 365.25M | 358.36M | 347.35M | 336.34M |
| Average Diluted Shares Outstanding | 372.14M | 365.25M | 358.36M | 347.35M | 336.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |